We classified four established DLBCL cell lines with differential expression of CD80 and CD86 (high/high, high/low, low/high, low/low) for in vitro trials and the CD80high/CD86high Raji cell line for in vivo experiments (Figures 2A and 2B). This evidence concerns the gene CD86 and diffuse large B-cell lymphoma.